Microbiome Profiling from Fecal Immunochemical Test Reveals Microbial Signatures with Potential for Colorectal Cancer Screening

dc.contributor.authorKhannous lleiffe, Olfat
dc.contributor.authorWillis, Jesse R.
dc.contributor.authorSaus, Ester
dc.contributor.authorMoreno Aguado, Víctor
dc.contributor.authorCastellví Bel, Sergi
dc.contributor.authorGabaldón, Toni
dc.contributor.authorThe Criprev Consortium
dc.date.accessioned2023-02-06T09:20:32Z
dc.date.available2023-02-06T09:20:32Z
dc.date.issued2022-12-25
dc.date.updated2023-02-03T11:53:15Z
dc.description.abstractSimple Summary Colorectal cancer (CRC) is a global healthcare challenge that involves both genetic and environmental factors. Several pieces of evidence suggest that alterations of the gut microbiome can influence CRC development. In the present study we analyzed 16S rRNA sequencing data from fecal immunochemical test (FIT) samples from a large cohort, observing a predictive potential of the microbiome, revealing changes along the path from healthy tissue to carcinoma. Our work has implications in the understanding of the roles of microbes on the adenoma to carcinoma progression and opens the door to an improvement of the current CRC screening programmes. Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Early diagnosis of CRC, which saves lives and enables better outcomes, is generally implemented through a two-step population screening approach based on the use of Fecal Immunochemical Test (FIT) followed by colonoscopy if the test is positive. However, the FIT step has a high false positive rate, and there is a need for new predictive biomarkers to better prioritize cases for colonoscopy. Here we used 16S rRNA metabarcoding from FIT positive samples to uncover microbial taxa, taxon co-occurrence and metabolic features significantly associated with different colonoscopy outcomes, underscoring a predictive potential and revealing changes along the path from healthy tissue to carcinoma. Finally, we used machine learning to develop a two-phase classifier which reduces the current false positive rate while maximizing the inclusion of CRC and clinically relevant samples.
dc.format.extent22 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2072-6694
dc.identifier.pmid36612118
dc.identifier.urihttps://hdl.handle.net/2445/193146
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers15010120
dc.relation.ispartofCancers, 2022, vol. 15, num. 1, p. 120
dc.relation.urihttps://doi.org/10.3390/cancers15010120
dc.rightscc by (c) Khannous lleiffe, Olfat et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer colorectal
dc.subject.classificationMicrobiota intestinal
dc.subject.classificationCribratge
dc.subject.classificationDiagnòstic
dc.subject.otherGastrointestinal microbiome
dc.subject.otherMedical screening
dc.subject.otherDiagnosis
dc.subject.otherColorectal cancer
dc.titleMicrobiome Profiling from Fecal Immunochemical Test Reveals Microbial Signatures with Potential for Colorectal Cancer Screening
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
cancers-15-00120-v2.pdf
Mida:
3.32 MB
Format:
Adobe Portable Document Format